Northwest Biotherapeutics (NWBO) Current Assets (2010 - 2026)

Northwest Biotherapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• In Q1 2026, Current Assets rose 32.35% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $6.2 million (up 32.35% YoY), while the FY2025 annual figure was $5.5 million, up 35.82% from the prior year.
• Current Assets for Q1 2026 stood at $6.2 million, up from $5.5 million in the prior quarter.
• The five-year high for Current Assets was $11.8 million in Q3 2022, with the low at $4.1 million in Q4 2024.
• The 5-year median for Current Assets is $6.2 million (2025), against an average of $6.7 million.
• The sharpest annual moves came in 2022 and 2023: Current Assets jumped 86.46% in 2022, then sank 56.23% in 2023.
• Northwest Biotherapeutics' Current Assets stood at $9.4 million in 2022, then tumbled by 56.23% to $4.1 million in 2023, then declined by 1.53% to $4.1 million in 2024, then surged by 35.82% to $5.5 million in 2025, then advanced by 12.42% to $6.2 million in 2026.
• Business Quant data shows NWBO's Current Assets at $6.2 million in Q1 2026, $5.5 million in Q4 2025, and $7.2 million in Q3 2025.